Vg Life Sciences Inc

PINK:VGLS USA Real Estate - Development
Market Cap
$2.11 Million
Market Cap Rank
#51361 Global
#16051 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
--
All Time High
$5400.00
About

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is … Read more

Vg Life Sciences Inc (VGLS) - Total Liabilities

Latest total liabilities as of September 2023: $4.56 Million USD

Based on the latest financial reports, Vg Life Sciences Inc (VGLS) has total liabilities worth $4.56 Million USD as of September 2023.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Vg Life Sciences Inc - Total Liabilities Trend (1999–2022)

This chart illustrates how Vg Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Vg Life Sciences Inc Competitors by Total Liabilities

The table below lists competitors of Vg Life Sciences Inc ranked by their total liabilities.

Liability Composition Analysis (1999–2022)

This chart breaks down Vg Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio N/A Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.00 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets N/A Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vg Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vg Life Sciences Inc (1999–2022)

The table below shows the annual total liabilities of Vg Life Sciences Inc from 1999 to 2022.

Year Total Liabilities Change
2022-12-31 $4.62 Million -7.77%
2021-12-31 $5.01 Million -43.15%
2020-12-31 $8.81 Million +14.04%
2019-12-31 $7.72 Million +32.47%
2014-12-31 $5.83 Million -7.98%
2013-12-31 $6.33 Million +119874.41%
2012-12-31 $5.28K -99.87%
2011-12-31 $4.10 Million -19.68%
2010-12-31 $5.11 Million +51.41%
2009-12-31 $3.38 Million -48.04%
2008-12-31 $6.50 Million +16.29%
2007-12-31 $5.59 Million -33.08%
2006-12-31 $8.35 Million +163.97%
2005-12-31 $3.16 Million +25.83%
2004-12-31 $2.51 Million -74.85%
2003-12-31 $9.99 Million +4.61%
2002-12-31 $9.55 Million +1.01%
2001-12-31 $9.46 Million +3783.12%
2000-12-31 $243.55K +57.13%
1999-12-31 $155.00K --